News 
Market Data 
Discover
Replies to post #1918 on ChromaDex Corp. (CDXC)
announced today that researchers from the University of Iowa found a way to reduce the risks of developing insulin resistance and sensory neuropathy (nerve damage) in mice with induced prediabetes and type 2 diabetes, using ChromaDex’s nicotinamide riboside (NR), NIAGEN®, which is a form of vitamin B3. The results of this study, published in the journal Scientific Reports, demonstrate that NR was successful at reducing fasting and non-fasting blood glucose levels, as well as weight gain, and was protective against sensory neuropathy in these groups.
“Prevention remains extremely important. This means maintaining a healthy level of physical activity and not overdoing calorie intake,” comments the study’s chief investigator and discoverer of nicotinamide riboside, Charles Brenner, PhD, professor and Roy J. Carver Chair of Biochemistry at the UI Carver College of Medicine and member of the ChromaDex Scientific Advisory Board, “But there are millions of people who are struggling with obesity as well as pre-diabetic and diabetic conditions. This research provides hope that we are on track to find potentially safe and effective nutritional approaches to improving whole-body metabolism, and protecting nerves from diabetic damage.”
In February 2016, ChromaDex announced the commencement of an obesity and diabetes collaborative human clinical study of NR with Dr. Jonas Treebak at the University of Copenhagen, which they hope will leverage and build upon Brenner’s findings.
NR- A Promising Vitamin
NR works by boosting NAD+, the essential metabolite required for cellular energy production. Aging, a sedentary lifestyle, and overeating can cause a decline in NAD+ levels which negatively impacts the efficiency and function of our mitochondria, the energy-producing powerhouses in every cell of our body.
Frank Jaksch, Jr., CEO and co-founder of ChromaDex, the supplier of the first and only commercially available form of NR, sold under the brand name NIAGEN® confirms, “NAD+ depletion is a nutrient deficiency story associated with the aging process which is why it is getting an unprecedented amount of attention in the research community. Over the past few years, there have been a tremendous number of high profile peer reviewed publications demonstrating the effectiveness of NR at boosting NAD+, and positively impacting aging and age related disease,” Jaksch stated.
Last month, a team headed by Dr. Johan Auwerx at EPFL in Switzerland, published a study in Science showing that mice taking NR lived longer than mice that did not. ChromaDex has signed over 67 collaborative agreements for research with universities globally since they launched NR in 2013. “Many of these studies are now publishing. NR is at a tipping point where the body of scientific evidence is too rich to ignore,” Jaksch commented.
AI
